Triamcinolone acetonide ER is a Small Molecule owned by Pacira BioSciences, and is involved in 20 clinical trials, of which 15 were completed, 4 are ongoing, and 1 is planned.

Triamcinolone acetonide extended release (FX-006) acts as glucocorticoid receptor (GR) agonist. It binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. It translocates into the nucleus and binds to DNA and changes genetic expression both positively and negatively. This results in synthesis of anti-inflammatory proteins. Consequently, an overall reduction in inflammation and autoimmune reactions are accomplished.

The revenue for Triamcinolone acetonide ER is expected to reach a total of $2.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Triamcinolone acetonide ER NPV Report.

Triamcinolone acetonide ER is currently owned by Pacira BioSciences.

Triamcinolone acetonide ER Overview

Triamcinolone acetonide (Zilretta/FX 006) is under development for the treatment of osteoarthritis pain of the shoulder. It is a synthetic glucocorticoid acts as anti-inflammatory agent. It is formulated as extended-release injectable suspension for intra-articular route of administration. Zilretta is indicated for the management of osteoarthritis pain of the knee. It is under development for the treatment of pain associated with mild to moderate osteoarthritis.

Triamcinolone acetonide is under development for the treatment of osteoarthritis pain of the shoulder, hip and bilateral knee. It is administered through intra-articular route. Triamcinolone acetonide acts by targeting glucocorticoid receptor.

Pacira BioSciences Overview

Pacira BioSciences (Pacira), formerly Pacira Pharmaceuticals Inc, provides non-opioid pain management and regenerative health solutions. The company develops drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic administered at the time of surgery to control pain and eliminate the use of opioids for acute postsurgical pain. Its other products include iovera, a non-opioid treatment intended to block pain, and relieve pain and symptoms related to osteoarthritis of the knee; among others. Its products are essentially used by hospitals, doctors and ambulatory surgery centers. The company sells products through co-promotion agreements and supply agreements with other pharmaceutical companies. The company has operations in the US and the UK. Pacira is headquartered in Tampa, Florida, the US.

The company reported revenues of (US Dollars) US$541.5 million for the fiscal year ended December 2021 (FY2021), an increase of 26% over FY2020. In FY2021, the company’s operating margin was 16.6%, compared to an operating margin of 8.9% in FY2020. In FY2021, the company recorded a net margin of 7.8%, compared to a net margin of 33.9% in FY2020. The company reported revenues of US$167.5 million for the third quarter ended September 2022, a decrease of 1.1% over the previous quarter.

Quick View – Triamcinolone acetonide ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Triamcinolone acetonide ER
Administration Pathway
  • Intraarticular
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.